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Feedforward Control of Coronary Blood Flow via Coronary a-Receptor Stimulation
Jody K. Miyashiro, Eric 0. Feigl
It is usually assumed that the increase in coronary blood flow observed with norepinephrine occurs through local metabolic vasodilation secondary to cardiac 3receptor activation. However, direct feedforward f3-receptor-mediated coronary vasodilation is also a possibility. In dogs with a-receptor blockade, the left circumflex artery was perfused at constant pressure. The vasodilator effect of intracoronary norepinephrine injections was determined during prolonged diastoles to avoid the chronotropic and inotropic effects of norepinephrine. Norepinephrine caused a dose-dependent increase in coronary blood flow that was attenuated by both the selective fl1-antagonist practolol and the selective }32-antagonist ICI 118 551. These data indicate that norepinephrine activates j31-and j-receptors in coronary resistance vessels to cause vasodilation independent of inotropic and chronotropic effects. The physiological significance of coronary j3-receptor-mediated vasodilation was investigated in the beating heart. The coronary blood flow response and coronary venous oxygen tension response were compared when myocardial oxygen consumption was increased over the same range by one of three positive inotropic interventions: (1) norepinephrine, (2) paired-pulse stimulation, or (3) norepinephrine after a-blockade. During norepinephrine infusion (intervention 1), coronary venous oxygen tension decreased, indicating that the match between myocardial oxygen consumption and oxygen delivery is not maintained when coronary blood flow is controlled by a-and fl-receptors in addition to local metabolic factors. Paired-pulse stimulation (intervention 2) also resulted in a decrease in coronary venous oxygen tension, demonstrating that the balance between oxygen consumption and delivery is not maintained when blood flow is controlled by local metabolic factors alone. However, when coronary 3-receptor-mediated vasodilation was unmasked by a-blockade, norepinephrine infusion (intervention 3) produced no change in coronary venous oxygen tension. Therefore, coronary 13-receptor vasodilation helps maintain the balance between flow and metabolism in a feedforward manner in the beating heart. (Circulation Research 1993;73:252-263) KEY WORDS * feedforward control * feedback control * coronary blood flow * norepinephrine I mportant physiological increases in myocardial oxygen consumption (MVo2) are mediated by the sympathetic nervous system through norepinephrine. The coronary vasodilation observed with norepinephrine is usually ascribed to the balance between the effects of a-vasoconstriction and local metabolic feedback vasodilation secondary to myocardial 31-receptormediated increases in heart rate and contractility.1 Both a-vasoconstriction and local metabolic feedback vasodilation in the heart are well established.1,2 By definition, metabolic feedback control requires an error signal reflecting an imbalance between metabolism and oxygen delivery for vasodilation to occur.
The hypothesis that only a-vasoconstriction and metabolic feedback control affect coronary blood flow during norepinephrine administration is challenged by the in vitro demonstration of coronary vascular fl-receptors1 and by recent in vivo evidence that the fl-agonist isoproterenol causes coronary 813and 182-mediated vasodilation independent of inotropic and chronotropic taining the balance between metabolism and coronary blood flow during increases in myocardial metabolism. The present results show that feedforward activation of coronary 31-and fl2-receptors, together with local metabolic feedback, helps maintain the balance between myocardial metabolism and oxygen delivery during norepinephrine-induced increases in MVo2.
Materials and Methods General Preparation
Thirty-six adult mongrel dogs of either sex weighing 24.5 to 34.5 kg were sedated with morphine sulfate (2.5 mg/kg s.c.) and anesthetized with a-chloralose (100 mg/kg i.v.). The anesthesia level was maintained by supplemental injection of 500 mg a-chloralose as needed. The metabolic acidosis associated with chloralose anesthesia was prevented by an infusion of 1.5% NaHCO3 and bolus injections of 8.4% NaHCO3 as required. The dogs were ventilated with oxygen-enriched room air by a positive-pressure respirator (model 607, Harvard Apparatus, South Natick, Mass) so that arterial oxygen tension was maintained above 90 mm Hg, carbon dioxide tension was 38.6+1.6 mm Hg, and H' concentration was 41.2±+2.6 nM (mean±+SD).
Body temperature was controlled with a heating pad and an esophageal thermostat set at 37°C (model 73A, Yellow Springs Instrument Co, Yellow Springs, Ohio). All experiments were carried out on closed-chest dogs. Aortic pressure was measured by a strain-gauge manometer (Statham P23 ID, Gould, Inc, Cleveland, Ohio) through a catheter inserted via either a femoral or brachial artery. The dogs received heparin sodium (750 U/kg i.v.) before femoral or coronary cannulation. Atropine (0.5 mg/kg i.v.) was given to prevent parasympathetic effects.
Femoral Cannulation
Twelve dogs were prepared for femoral experiments in the manner described by Trivella et al.3 A short piece of Silastic tubing with an electromagnetic flow transducer (model SWF-5RD, Zepeda Instruments, Seattle, Wash) in line was placed in the right femoral artery for measurement of hind limb blood flow. A needle was inserted into the tubing distal to the flow transducer for intra-arterial drug administration. The right ankle was tied off to prevent flow to the paw so that the vascular bed under study was predominantly skeletal muscle.
Heart Block and Cardiac Pacing
Closed-chest atrioventricular heart block was produced using the method described by Ito and Feigl.5 Briefly, a cannula was advanced down the right external jugular vein and, under fluoroscopic visualization, positioned at the level of the atrioventricular (AV) node. A needle housed inside the cannula was advanced into the AV nodal tissue, and a saturated lead acetate-formaldehyde solution was injected. The cannula was replaced by a pacing wire (No. 5651, USCI, Billerica, Mass) that was positioned in the right ventricular apex, and the heart was paced throughout the experiment. Encainide (2 mg/kg i.v.) and lidocaine (20 to 60 mg i.v., as needed) were administered to suppress ectopic beats. In addition, lidocaine was infused (1.72 to 3.44 mg/min i.v.) during the asystole experiments, and pentobarbital so-dium (1 mg/kg i.v.) was administered during the pacing experiments.
Left Circumflex Coronary Artery Cannulation
The preparation for the asystole experiments is described by Trivella et al.3 Briefly, the left circumflex coronary artery of 15 closed-chest dogs was cannulated with a wedge-tip stainless-steel cannula advanced through the right carotid artery. The left circumflex artery was perfused with blood from a femoral artery. Coronary arterial pressure was measured at the tip of the cannula via an inner tube and strain-gauge manometer (Statham P23 ID, Gould). A servo-controlled roller pump maintained mean coronary pressure at 100 mm Hg. Coronary blood flow was measured in the extracorporeal circuit by an electromagnetic flow transducer (model SWF-SRD, Zepeda Instruments). Mean coronary blood flow was determined by averaging the phasic flow with a 2.0-second time constant. The flowmeter was calibrated using timed volume collections of blood at the end of the experiment.
The seal between the cannula tip and coronary artery was tested in two ways. At the beginning of each experiment, nitroglycerin (10 ,ug in 0.5 mL saline) was injected into a side tube that opened to the outside of the cannula just proximal to its tip. If there was no flow response to nitroglycerin injected into the side tube but there was a twofold or more increase in flow when nitroglycerin was injected directly into the perfusion line, the seal was considered satisfactory. At the end of each experiment, crystal violet dye suspended in 10% ammonium hydroxide was injected into the cannula while coronary perfusion pressure was held 50 mm Hg above aortic pressure. Staining of perfused myocardium and vessels but not the area proximal to the cannula tip indicated a good seal around the tip. The weight of the stained tissue was used to compute the flow per gram of perfused myocardium.
Left Main Coronary Artery Cannulation
For the pacing experiments, the left main coronary artery was cannulated in nine closed-chest dogs with a balloon-tipped stainless-steel cannula inserted via the right carotid artery (Fig 1) . The coronary artery was pump-perfused at 90 mm Hg as in the study by Broten et a12 using the same servo-controlled extracorporeal circuit and electromagnetic flowmeter as described above for the left circumflex cannulation. The seal of the balloon-tip cannula in the coronary ostium was considered satisfactory if injection of crystal violet at the end of the experiment, while coronary pressure was maintained 50 mm Hg above aortic pressure, stained perfused myocardium and vessels but not the ascending aorta. If this criterion was not met, the animal was excluded from the study. The weight of the stained tissue was used to compute the flow per gram of perfused myocardium.
Coronary Sinus Cannulation and Coronary Venous Blood Gases
For the pacing experiments, a right heart catheter (SF JR-4, USCI) was advanced in the right external jugular vein and into the coronary sinus under fluoroscopic visualization (Fig 1) . Coronary venous blood was continuously withdrawn with a roller pump (model 7013, After atrioventricular (A-V) heart block, the heart was paced at 75 beats per minute via a pacing wire in the right ventricle. The coronary sinus was cannulated, and coronary venous blood was withdrawn for sampling with a roller pump at a rate of 5 to 15 mL!min. Excess coronary venous blood was returned through a femoral vein (Fem. v.). The left main coronary artery was cannulated with a balloon-tipped cannula and pump-perfused at a constant pressure of 90 mm Hg with blood from the left femoral artery (Fem. a.). Coronary blood flow was measured with an electromagnetic (EM) flowmeter in the extracorporeal circuit. Coronary arterial blood samples were drawn directly from the extracorporeal circuit. Drugs were administered distal to the flowmeter.
Cole-Parmer Instrument Co, Chicago, Ill) to a sample port, and excess was returned to the dog via a femoral vein. A metal ring around the tip of the coronary sinus catheter prevented venous collapse during blood withdrawal. Right atrial admixture was prevented by placement of the catheter at least 15 mm into the coronary sinus and withdrawing blood at a rate of 5 to 15 mL/min. 6 The position of the tip of the right heart catheter was confirmed post mortem (32 to 45 mm from the coronary sinus ostium), and the pump rate and tubing transit time were determined. Transit times ranged from 6.3 to 9.6 seconds. Repeated coronary venous blood samples were taken for gas analysis (model 1302, Instrumentation Laboratories, Lexington, Mass) during the hemodynamic steady state before and after increases in MVo2. The coronary venous Po2 values plotted in Fig 5 have been shifted along the time axis to account for the transit time delay. The Po2 and Pco2 for each metabolic state were averaged for data analysis.
A subset of arterial and coronary venous samples was analyzed for oxygen content by the fuel-cell method (Lex-02-Con, Lexington Instruments Corp, Waltham, Mass), and hemoglobin was determined by the cyanmethemoglobin method. A computer subroutine7 was used to calculate oxygen content from the blood gas tensions, pH, and hemoglobin values. The Lex-02-Con values were used to construct a calibration curve for the blood gas subroutine. MVo2 was calculated as the product of coronary flow and the difference in arteriovenous oxygen content and expressed as microliters of oxygen per minute per gram of myocardium.
Lactate Metabolism
In the pacing experiment, arterial and coronary venous blood samples were drawn during the control period and at the end of the steady-state elevation of MVo2 to determine whether the increases in MVo2 were accompanied by net myocardial lactate production. The samples were immediately placed in vials containing NaF to prevent glycolysis and placed on ice. Lactate concentration was measured by a lactate analyzer (model 23A, Yellow Springs Instruments). Percent myocardial lactate extraction was calculated as arterial (a) minus coronary venous (v) divided by arterial lactate a-v concentration ( x 100). a
a-Adrenergic Receptor Blockade
In all experiments, the noncompetitive a-adrenergic antagonist phenoxybenzamine was infused directly into either the femoral or coronary vascular bed for 10 minutes, and the preparation was allowed to stabilize for 30 minutes while phenoxybenzamine took effect.8 The purpose of administering phenoxybenzamine was twofold. First, the postjunctional a-receptors were blocked in order to blunt the a-mediated vasoconstrictor effect of norepinephrine and unmask 3-receptor vasodilation. Second, the prejunctional a-receptors that inhibit endogenous norepinephrine release9 were blocked to avoid confounding dose-response curves with variable amounts of norepinephrine release.
Femoral Experimental Design
The selectivity of the 13-antagonists was tested in the femoral bed that only has 12-receptors.3 Twelve dogs received a femoral arterial infusion of the nonselective a-receptor antagonist phenoxybenzamine (0.5 to 1 mg/ kg) to prevent a-mediated vasoconstriction with norepinephrine and leave 13-receptors unopposed. Logarithmically increasing bolus doses (0.2 mL) of norepinephrine (0.1 to 3 ,gg/kg) were injected directly into the femoral arterial cannula. The response of the hind limb vasculature was quantified as the change in vascular conductance (milliliters per minute per millimeters of mercury). The response to a vehicle injection (0.2 mL) was tested before and after each dose-response curve. The average vehicle response was subtracted from each norepinephrine response to obtain the change in femoral conductance due to norepinephrine. The norepinephrine dose-response curve was repeated after treatment with the selective 1,3-antagonist practolol10 (10`6 mol/kg i.v.) or the selective 132-antagonist ICI 118 55111 (10`6 mol/kg i.v.).
Asystole Experimental Design
To classify the coronary vascular 13-receptors that are activated by norepinephrine, a preparation was required that would not manifest the local metabolic vasodilation that occurs secondary to activation of myocardial p-receptors. Therefore, a nonbeating cardiac preparation without chronotropic or inotropic effects was used, in a preparation previously described by Trivella et al. 3 Fifteen dogs underwent atrioventricular heart block and left circumflex cannulation and received an intracoronary arterial infusion of phenoxybenzamine (1 mg/kg) before the experiment. Bolus injections (0.2 mL) of either saline vehicle or logarithmically increasing doses of norepinephrine (0.1 to 3 ,ug/kg) were made directly into the coronary perfusion line. Simultaneously, the pacing stimulator was switched off until after the peak vasodilation produced by norepinephrine was observed. Asystoles with vehicle injections were alternated with asystoles with norepinephrine injections. Coronary flow with vehicle (before and after a dose of norepinephrine) was determined at the corresponding duration of the asystole for the peak norepinephrine effect. The vehicle responses before and after a norepinephrine injection were averaged and subtracted from the peak norepinephrine response to obtain the change in flow due to norepinephrine (Fig 3) . If premature ventricular contractions occurred during the dose-response curve, the vehicle or norepinephrine dose was repeated. A single premature ventricular contraction occurring far from the peak vasodilation was considered acceptable. The dose-response curve for norepinephrine was repeated after administration of an intravenous dose of a selective 6,-antagonist (practolol, 10`mol/kg) or /32-antagonist (ICI 118 551, 10`6 mol/kg).
Pacing Experimental Design
The main difficulty in studying the effect of norepinephrine on coronary fl-receptors in vivo is demonstrating whether the observed vasodilation with norepinephrine is due to direct stimulation of coronary ,B-receptors or to local metabolic feedback vasodilation secondary to the increased MVo2 when myocardial 8-receptors are activated. This experiment was designed to distinguish the direct effects of norepinephrine on coronary vascular resistance from the local metabolic effects by comparing the resulting balance between metabolism and flow when MVo2 is increased via an increase in heart rate and contractility by (1) norepinephrine infusion, which affects blood flow through coronary a-and fl-receptor activation as well as through local metabolic feedback, and (2) paired-pulse pacing, which affects blood flow by local metabolic feedback without coronary a-and fl-receptor activation. The balance between metabolism and flow was indicated by the change in myocardial gas tensions, as measured by coronary venous Po2 and Pco2. Nine dogs underwent atrioventricular heart block, left main coronary artery cannulation, and coronary sinus catheterization. After a control period during which the heart rate was 75 beats per minute (except in one dog whose heart rate was 90 beats per minute), MVo2 was augmented by infusing norepinephrine directly into the coronary perfusion line (0.25 ,g/kg per minute) while making a step increase in paced heart rate to 150 beats per minute. During the control period and the period of increased MVo2, arterial and coronary venous blood samples were drawn for the measurement of Po2, Pco2, and pH as described above. After another control period at 75 beats per minute, MVo2 was increased by going from 75 beats per minute at single pace to 150 beats per minute at paired pace (postextrasystolic potentiation). Within each dog, both methods involved the same change in heart rate (75 to 150 beats per minute) and about the same increase in MVo2, but the increase in myocardial contractility was produced with norepinephrine in one case and with paired-pace stimulation in the other.
After both norepinephrine and paired-pacing runs were completed, the dogs received an intracoronary infusion of phenoxybenzamine (0.5 to 1 mg/kg) to blunt the a-receptor effects and unmask the 13-receptor vasodilation. The hypotension due to a-receptor blockade was combated by infusing 500 mL of 10% dextran (molecular weight, 40 000) in saline. This resulted in a hemodilution, with the arterial hemoglobin concentration decreasing from 16.0 to 11.6 g/dL ( Table 3 ). The norepinephrine and the paired-pacing runs were repeated after a-receptor blockade. In six dogs, the paired-pacing run was done before a-receptor blockade, in one dog it was done after a-blockade, and in two dogs paired pacing was done before and after a-blockade. The results were similar whether the paired-pacing run was done before or after a-blockade. In the dogs with two pacing runs, the results for all variables before and after a-blockade were averaged and treated as one run for statistical analysis.
Drugs
Phenoxybenzamine hydrochloride (Dibenyline, 0.5 to 1.5 mg/kg, Smith Kline & French Laboratories, Philadelphia, Pa) was infused into the femoral or coronary artery for nonselective a-adrenergic blockade. Practolol (10-6 mol/kg i.v.; molecular weight, 266.3; Imperial Chemical Industries, Macclesfield, England) was used to block fl1receptors; ICI 118 551 (10-6 mol/kg i.v.; molecular weight, 313.9; Imperial Chemical Industries) was dissolved in distilled water and was used in blocking fl2-receptors. The vehicle for norepinephrine [(-)-arterenol bitartrate salt, Sigma Chemical Co, St Louis, Mo] was 0.9% saline, with 6 mg/L EDTA as an antioxidant.
To suppress ectopic beats, encainide HCl (2 mg/kg, Bristol-Myers Co, Evansville, Ind) and 2% lidocaine HCl (1.72 to 3.44 mg/min and 20 to 60 mg, as needed; Elkins-Sinn, Inc, Cherry Hill, NJ) were given intravenously. In the pacing experiments, a small dose of pentobarbital sodium (Nembutal, 1 mg/kg i.v., Abbott Laboratories, North Chicago, Ill) was also given to suppress ectopic beats. Atropine (atropine sulfate salt, 0.5 mg/kg i.v., Sigma) was administered to prevent a change in parasympathetic activity during norepinephrine injections. To prevent complement and white blood cell activation caused by blood-extracorporeal tubing interactions12 and changes in prostaglandin synthesis with catecholamines,13 aspirin (325 mg p.o., one day before the experiment) was administered in the pacing experiments, and ibuprofen (12.5 mg/kg i.v.) was given in the asystole and femoral experiments. Ibuprofen (Sigma) was dissolved in 0.2 M sodium carbonate at a concentration of 25 mg/mL, and pH was adjusted between 7.5 and 8 with 1N HCl.
Data Analysis and Experimental Criteria
Six randomized block analyses of variance were performed for the dose-response experiments, and one was TIME CONTROL APo2 versus A1MVo2 (APo0!AMVo2) line per dog per intervention ( Fig 6) . Mean APo2/AMVo2 slopes per intervention were compared using t tests with the standard deviation estimated from the analysis of variance. All data values are reported as mean+SEM. For the pacing experiment, two prospective experimental criteria were set. The first criterion was to ensure that the preparation was within the normal range of metabolic control where coronary venous oxygen tension is below 25 mm Hg, as in the study by Broten et al.2 This upper limit was set to avoid data from vasodilated preparations, since autoregulation is diminished above 25 mm Hg. 15 The second criterion was that cardiac lactate extraction be greater than 10%. Lactate extraction of less than 10% was considered to be an indication of pathological anaerobic metabolism.16'17
Results

Femoral Experiments
Norepinephrine augmented hind limb vascular conductance in the a-blocked dog in a dose-dependent manner. The different actions of the selective /-antagonists on the norepinephrine dose-response curve are shown in Fig 2. The dose-response curve was not significantly affected by the /3,-antagonist practolol. In contrast, administration of the 3,2-antagonist ICI 118 551 resulted in a downward shift of the norepinephrine dose-response curve (P<.001). Aortic pressure and initial hind limb vascular conductance before and after the antagonists are given in Table 1 .
These data demonstrate that norepinephrine produces vasodilation via /32-adrenergic receptors in the a-blocked femoral vascular bed. This experiment confirms the findings of previous studies in which /,2receptors were identified in the femoral vascular bed by using isoproterenol.3
Asystole Experiments
Cessation of pacing with vehicle injection led to a decline in coronary blood flow despite constant coronary perfusion pressure (Fig 3) . In contrast, an intracoronary injection of norepinephrine (shown by the arrow) during asystole after a-receptor blockade resulted in an increase in coronary blood flow even though the heart was stopped.
The coronary vasculature vasodilated in a dose-dependent manner with norepinephrine after a-adrenergic blockade, as shown in Fig 4. The response to norepinephrine was stable over two dose-response curves. After the administration of practolol, the norepinephrine dose-response curve was shifted downward (P<.005). The /32-antagonist ICI 118 551 caused a sim- norepinephrine plus pacing tachycardia after a-blockade. The arrows indicate the point at which the norepinephrine infusion was started. When MVo2 was augmented by intracoronary norepinephrine infusion at 150 beats per minute ( Fig 5A) , coronary blood flow increased to a new steady state, yet coronary venous Po2 fell. Coronary blood flow also increased with paired pacing at 150 beats per minute ( Fig SB) while coronary venous Po2 decreased. However, when norepinephrine infusion was combined with pacing at 150 beats per minute after a-blockade (Fig SC) , the rise in coronary flow matched the rise in MVo2, and coronary venous Po2 was unchanged.
The baseline values and average responses of nine dogs to the three interventions are given in Table 3 The relation between MVo2 and coronary venous P02 for nine dogs during each of the interventions is shown in Fig 6. The decline in coronary venous P02 with norepinephrine indicates that the coronary response, which is dependent on coronary adrenergic receptor activation as well as local metabolic vasodilation, was insufficient to meet the increased oxygen demand caused by the elevated heart rate and increased contractility. During paired-pulse stimulation when adrenergic receptors were not activated, local metabolic vasodilation alone did not adequately increase coronary flow to match the increased MVo2; as a result, coronary venous Po2 fell. However, when a-receptors were blocked, norepinephrine administration at the high heart rate did not alter the coronary venous Po2. The Table 4 ).
ilar shift in the norepinephrine dose-response curve (P<.001). The changes in aortic pressure and basal coronary flow before and after the antagonists are reported in Table 2 .
These results demonstrate that norepinephrine stimulates coronary vascular 81-and j32-adrenergic receptors to cause vasodilation independent of cardiac inotropic and chronotropic effects during prolonged asystoles. Fig S shows the response of one dog when MVo2 was increased during constant coronary perfusion pressure
Pacing Experiments
Discussion
The present study demonstrates that norepinephrine vasodilates the a-receptor-blocked femoral vascular bed by activating 132-adrenergic receptors. The experiments in the femoral bed confirm that practolol is selective for ,31-receptors at the dose used in this study and that ICI 118 551 is an effective J82-blocking agent. In the coronary circulation, both practolol and ICI 118 551 decreased the vasodilation due to norepinephrine during prolonged asystoles (Fig 4) . This demonstrates that norepinephrine causes vasodilation in coronary resistance vessels via ,13and 12-receptors independent of chronotropic and inotropic effects. The physiological significance of coronary ,B-receptormediated vasodilation was investigated in the beating heart. The coronary blood flow response and coronary venous Po2 response were compared when MVo2 was increased over the same range by pacing tachycardia plus one of three positive inotropic interventions: (1) norepinephrine, (2) paired-pulse stimulation, or (3) norepinephrine after a-blockade ( Fig 6) . During norepinephrine infusion plus pacing tachycardia, coronary blood flow increased, yet coronary venous Po2 decreased, indicating that the match between MVo2 and oxygen delivery is not maintained when coronary blood flow is controlled by aand ,3-receptors in addition to local metabolic factors. Paired-pulse stimulation plus pacing tachycardia also resulted in an increase in coronary blood flow but a decrease in coronary venous Po2, demonstrating that the balance between oxygen consumption and delivery is not maintained when blood flow is controlled only by local metabolic factors. However, when coronary p-receptormediated vasodilation was unmasked by a-blockade, norepinephrine infusion plus pacing tachycardia resulted in an increase in coronary blood flow, and coronary venous Po2 did not change (see Table 4 ). Therefore, coronary /-receptor vasodilation helps maintain the balance between flow and metabolism in a feedforward manner in the beating heart.
Femoral Experiments
In the present study, norepinephrine vasodilation in the femoral bed was unmasked by the noncompetitive a-adrenergic antagonist phenoxybenzamine. Phenoxybenzamine was also administered to block prejunctional a-receptors and prevent variable endogenous norepinephrine release9 during dose-response curves.
In the a-blocked dog, norepinephrine (0.1 to 3 ,ug/kg) caused dose-dependent increases in hind limb blood flow that were unaffected by practolol and attenuated by ICI 118 551 (Fig 2) . The antagonist doses used (10`6 mol/kg) were based on a previous study in this laboratory in which the /31-antagonist practolol and the /82antagonist ICI 118 551 were found to be still selective at 
Asystole Experiments
The main difficulty in studying p-receptor function in the coronary arteries is the presence of 13-receptors on myocardial cells. Activation of myocardial /3-receptors results in tachycardia and an increase in contractility. These positive chronotropic and inotropic effects lead to an increase in MVo2, which in turn leads to local metabolic vasodilation.' Various methods have been used to overcome the problem of myocardial /-receptor activation and local metabolic vasodilation when characterizing coronary /-receptors. In some studies, it was assumed that myocardial receptors were of the 3,1 subtype, and an attempt was made to avoid the metabolic effects by administering a selective /,-antagonist. The usual conclusion was that coronary receptors are of the 82 subtype, but these studies were inherently incapable of demonstrating vascular 831-receptors because any coronary X31-activation was already blocked.
Furthermore, /32-receptors have been reported, in addition to f31-receptors, in autoradiographic20 and radioligand-binding21 studies of myocardial tissue. These myocardial A-receptors appear to have positive inotropic20 and chronotropic22323 effects that could contribute to metabolic vasodilation. It has been suggested that cardiac tissue may also contain /83-adrenoceptors that cause myocardial stimulation24 and lead to metabolic vasodilation. Therefore, the conclusions of studies that attempt to pharmacologically determine the presence and subtype of coronary 3-receptors based on changes in coronary flow in the beating heart are ambiguous.1 '25-27 The first evidence of direct coronary /3-receptormediated vasodilation was obtained by Klocke et al,28
who observed the oxygen balance during an intravenous infusion of the nonselective /3-agonist isoproterenol.
During the infusion, coronary venous Po2 increased, indicating vasodilation in excess of metabolic demand. Since coronary venous Po2 did not decrease as might have been expected had the vasodilation occurred secondary to metabolism, the investigators reasoned that direct coronary ,B-mediated vasodilation was involved. In the present study, prolonged diastoles were used to avoid vasodilation secondary to chronotropic and inotropic effects. This experimental design is not dependent on knowing the myocardial 13-receptor subtype. During cessation of pacing, norepinephrine administration resulted in a dose-dependent coronary vasodilation that was attenuated by the 81-antagonist practolol (10`6 mol/kg) and the }32-antagonist ICI 118 551 (10`6 mol/ kg). The selectivity of these antagonist doses was demonstrated previously3 and confirmed in the femoral experiments of the present study. The possibility that the observed vasodilation was due to reflex parasympathetic activation31 or to changes in prostaglandin syn-thesis13 was prevented by administration of atropine and ibuprofen before the experiment. Therefore, the present results demonstrate that norepinephrine activates coronary f.-and 832-receptors to increase coronary blood flow, independent of chronotropic and inotropic effects. This conclusion is in agreement with a previous study from this laboratory in which isoproterenol vasodilated the canine coronary vasculature during long diastoles via coronary I1-and P32-receptors.3
The changes in coronary blood flow observed during constant pressure perfusion in the present experiment ierally reflect changes in resistance vessels rather Ln changes in large epicardial arteries because epidial vessels only contribute 2% to 5% of total coroy resistance under normal conditions.3233 ln studies of isolated coronary arteries, the investigas concluded that decreases in isometric tension are diated mainly by 813-receptors.1"34-39 These observans are in contrast to the present study and another in 3 study in the nonbeating heart that show vasodilan to be mediated by both coronary I31-and 82eptors. 3 The response of isolated vessels to catecholines and the failure to demonstrate 832-receptors in o may be affected by in vitro conditions, such as ionic itent, pH, and temperature of the isolated vessel bath ution,40 or the condition of the endothelium, changes prostaglandin synthesis, and the agents used for contraction.134142 rhe discrepancy between the conclusions of the presstudy and studies on isolated coronary arteries may D be due to differences in the size of the vessels being died. Resistance vessels were investigated in the sent experiment, whereas large epicardial vessels are ally studied with in vitro techniques. Zuberbuhler Bohr43 demonstrated that large and small coronary FIG 6. Graph showing the relation between myocardial oxygen consumption (MVo2) and the coronary venous P02 during each of the three interventions. Coronary venous P02 decreased with MVo2 during pacing tachycardia plus norepinephrine and during pacing tachycardia plus paired-pulse stimulation. In contrast, coronary venous P02 did not change with pacing tachycardia plus norepinephrine after a-blockade. The Po2 response with paired-pulse stimulation shows the effect of metabolic feedback regulation of coronary blood flow alone. The difference between the response to norepinephrine before and after a-blockade shows the a-vasoconstrictor component of coronary flow control. The difference between the response to paired-pulse stimulation and the response to norepinephrine after a-blockade demonstrates the coronary /3-vasodilator component of coronary blood flow control. Thus coronary 13-receptor-mediated vasodilation helps maintain the balance between metabolism and flow in a feedforward manner during norepinephrine infusion in the beating heart. arteries respond differently to catecholamines. This difference could be due to a segmental distribution of aand p-receptors, with a higher density of p-receptors in resistance vessels than in large vessels. 42 The resistance vessels may contain both p3l-and P2-receptor subtypes,
whereas large epicardial vessels have p1-receptors and only a minor population of :2-receptors.
Radioligand binding and autoradiographic studies support the hypothesis that there is a segmental distribution of P1-and p2-receptors along the coronary vascular tree. Autoradiographic studies have shown that the density of pl-receptors is inversely related to the coronary vessel diameter.44 Canine arterioles with a diameter of 20 to 70 gm contain a receptor population that is approximately 90% 132 and 10% p1,45 whereas large epicardial arteries have a ratio of 85% p1 to 15% p2. 46 These autoradiographic results are in agreement with the conclusions of radioligand-binding studies in which both ,1-and P2-receptors are found on membrane homogenates of large epicardial vessels, with a greater proportion of /,3-than P32-receptors,26,34,4748 whereas smaller epicardial branches contain predominantly P2receptors.48 Although autoradiographic and radioligand binding studies allow identification of P-receptor subtypes and support the findings of the present study, these techniques do not describe the function of these p-receptors. The pB-receptors identified by radioligand binding techniques may have a function unrelated to coronary vessel relaxation.
In summary, the vasodilator response to norepinephrine was evaluated in the a-blocked dog during prolonged diastoles to avoid myocardial effects on coronary blood flow. The vasodilation due to norepinephrine was dose dependent and was attenuated by P1and 02antagonists. The results indicate that norepinephrine activates both f31-and P2-receptors in canine coronary resistance vessels to increase coronary blood flow independent of chronotropic and inotropic effects.
Pacing Experiments
The demonstration that norepinephrine directly activates coronary /31-and P2-receptors in the nonbeating heart leads to the interesting question of the physiological role of coronary p-receptors in maintaining the balance between flow and metabolism during catecholamine-induced increases in myocardial metabolism in the beating heart.
Norepinephrine is known to cause vasodilation that is opposed by a-vasoconstriction in the coronary circulation.1 It has often been proposed that this vasodilator influence during exposure to norepinephrine is solely due to local metabolic feedback secondary to cardiac P-mediated increases in heart rate and contractility.'
When heart rate or contractility increases, MVo2 increases, and a small error signal develops that feeds back on the coronary vasculature to increase blood flow and correct the imbalance. The demonstration that coronary fil-and 12-receptors are activated by norepinephrine in the nonbeating heart challenges the traditional view that feedback alone increases coronary blood flow during norepinephrine-induced increases in myocardial metabolism.
To determine the contribution of coronary p-mediated vasodilation in the final balance between metabolism and flow, the metabolic error signal was measured when MVo2 was increased to the same extent while coronary blood flow was affected by (1) local metabolic feedback plus a-vasoconstriction plus ,-vasodilation, (2) local metabolic feedback alone, or (3) local metabolic feedback plus P-vasodilation; these situations were achieved by (1) pacing tachycardia plus norepinephrine, (2) pacing tachycardia plus paired-pulse stimulation, and (3) pacing tachycardia plus norepinephrine after a-blockade, respectively. A decrease in MVo2, as measured by coronary venous Po2, was considered the error signal that indicates the balance between oxygen delivery and MVo2.
A comparison of the coronary venous Po2 response during paired-pulse stimulation and during norepinephrine after a-blockade reveals the /3-vasodilator effect of norepinephrine. The differences between responses also reveal a-vasoconstriction and local metabolic vasodilation. The individual and combined effects of local metabolic vasodilation, a-vasoconstriction, and /3-vasodilation on the resulting coronary venous Po2 are summarized in Table 4 . Local metabolic factors increase coronary blood flow but not enough to prevent a fall in coronary venous Po2. a-Vasoconstriction also decreases coronary venous Po2, confirming previous findings,49 whereas p-vasodilation increases Po2. When /3-vasodila.tion is combined with local metabolic feedback, the decrease in Po2 is prevented. When f3-vasodilation is combined with local metabolic feedback with a-receptors intact, the /8-vasodilator effect is masked by a-vasoconstriction, and coronary venous Po2 decreases. Therefore, in both the adrenergically intact and the a-blocked dog, vasodilation mediated by coronary fl-receptors helps maintain the balance between metabolism and flow and minimizes the fall in coronary venous Po2 during increases in MVo2. The response to norepinephrine is a demonstration of an open-loop feedforward control system in which there is parallel activation of myocardial metabolism and vasodilation. With parallel activation, a metabolic error signal is not necessary for the flow response. If feedforward undercompensates or overcompensates for changes in metabolism, feedback acts to correct the error signal. The present results indicate that feedforward control occurs during norepinephrine infusion; however, it remains to be demonstrated that feedforward vasodilation is active during cardiovascular reflexes and exercise.
In a previous study by von Restorff and Bassenge,50 a transient increase in coronary venous oxygen saturation was observed with bolus intravenous injections of norepinephrine. The investigators reasoned that the overshoot in oxygen saturation was due to direct activation of coronary p-receptors and not due to feedback regulation because feedback systems do not overcompensate for a perturbation. Although this is true of the steadystate feedback response, feedback systems may overshoot after a perturbation before reaching a steady state. The interpretation of this previous study is difficult since steady-state responses were not achieved.
It has been suggested that the coronary response that is observed with norepinephrine is partly due to baroreflex activation of the parasympathetic nervous system,50 resulting in cholinergic-induced coronary vasodilation. 31 Since all dogs used in the present study received atropine before the experiment, it is unlikely that reflex parasympathetic effects contributed to the observed coronary response. Intracoronary norepinephrine infusions were used in the present study because the response is more reproduceable than sympathetic nerve stimulation, and the chest does not need to be opened. The relative coronary versus cardiac effects of infused norepinephrine may be different from norepinephrine released from sympathetic nerves that course along the coronary vessels in the heart. The 3-adrenergic feedforward control of coronary blood flow during cardiovascular reflexes remains to be studied.
Heart rate and coronary perfusion pressure may affect the balance between metabolism and flow. In the present experiment, the differences between responses were independent of heart rate and perfusion pressure, because the coronary circulation was perfused at a constant pressure of 90 mm Hg and each intervention involved the same change in heart rate (75 to 150 beats per minute). Dextran was given to combat the hypotensive effects of a-receptor blockade. This resulted in hemodilution, with arterial hemoglobin concentration falling from approximately 16 to 11.6 g/dL. However, this did not change the baseline coronary oxygen extraction or coronary venous oxygen tension (Table 3 ). In the two experiments in which paired pacing was done before and after a-receptor blockade, the fall in coronary venous P02 was greater after a-blockade in one dog and before blockade in the other dog. For these two dogs, the average fall in coronary venous Po2 was 3.0 mm Hg before a-blockade and 2.3 mm Hg after a-blockade. Also, a previous study demonstrated that cardiac pacing after adrenergic blockade decreases coronary venous P02.2 A comparison of the norepinephrine response before and after a-receptor blockade (Fig 6) demonstrates the well-known a-receptor-mediated coronary vasoconstriction. It seems paradoxical that there should be simultaneous activation of a-vasoconstriction and 8-vasodilation. However, these two apparently conflicting effects may serve two synergistic functions. Huang and Feigl5s demonstrated that a-vasoconstriction helps maintain blood flow to the inner layer of the left ventricle during exercise. The postulated mechanism is that a-vasoconstriction in large and medium-sized coronary arteries lessens the to-and-fro oscillation of flow from subendocardium to subepicardium during systole and diastole and thus preserves subendocardial flow during tachycardia. 52 The direct /-vasodilation demonstrated in the present study probably occurs mostly in small arterioles and serves to match blood flow and myocardial metabolism. This interpretation is consistent with the segmental distribution of coronary f-receptors reviewed above and the observation that a-vasoconstriction occurs in coronary arterial vessels larger than 100 ,um in diameter.53 Thus a-vasoconstriction functions to adjust phasic coronary impedance that preserves flow to the inner layer of the left ventricle, whereas f3-vasodilation prevents large decreases in tissue oxygen tension.
In conclusion, norepinephrine directly activates 31and 832-receptors in coronary resistance vessels and increases coronary blood flow in the absence of chronotropic and inotropic effects in the nonbeating dog heart. In the beating heart with or without a-receptor blockade, norepinephrine-induced increases in MVo2 are accompanied by coronary 8-receptor-mediated vasodilation that helps maintain the balance between myocardial metabolism and coronary blood flow in a feedforward manner. The response to norepinephrine is a demonstration of a feedforward control system in which the same stimulus that increases myocardial metabolic demand promptly increases oxygen delivery without the necessity of generating a metabolic error signal. In this system, feedback serves to correct the feedforward response if feedforward undercompensates or overcompensates for changes in metabolism.
